Regulatory  ||| S:0 E:11 ||| JJ
challenges  ||| S:11 E:22 ||| NNS
associated  ||| S:22 E:33 ||| VBN
with  ||| S:33 E:38 ||| IN
conducting  ||| S:38 E:49 ||| VBG
multicountry  ||| S:49 E:62 ||| JJ
clinical  ||| S:62 E:71 ||| JJ
trials  ||| S:71 E:78 ||| NNS
in  ||| S:78 E:81 ||| IN
resource-limited  ||| S:81 E:98 ||| JJ
settings  ||| S:98 E:107 ||| NNS
International  ||| S:107 E:121 ||| JJ
public  ||| S:121 E:128 ||| JJ
health  ||| S:128 E:135 ||| NN
and  ||| S:135 E:139 ||| CC
infectious  ||| S:139 E:150 ||| JJ
diseases  ||| S:150 E:159 ||| NNS
research  ||| S:159 E:168 ||| NN
has  ||| S:168 E:172 ||| VBZ
expanded  ||| S:172 E:181 ||| VBN
to  ||| S:181 E:184 ||| TO
become  ||| S:184 E:191 ||| VB
a  ||| S:191 E:193 ||| DT
global  ||| S:193 E:200 ||| JJ
enterprise  ||| S:200 E:211 ||| NN
transcending  ||| S:211 E:224 ||| VBZ
national  ||| S:224 E:233 ||| JJ
and  ||| S:233 E:237 ||| CC
continental  ||| S:237 E:249 ||| JJ
borders  ||| S:249 E:257 ||| NNS
in  ||| S:257 E:260 ||| IN
organized  ||| S:260 E:270 ||| JJ
networks  ||| S:270 E:279 ||| NNS
addressing  ||| S:279 E:290 ||| VBG
high-impact  ||| S:290 E:302 ||| JJ
diseases ||| S:302 E:310 ||| NNS
.  ||| S:310 E:312 ||| .
In  ||| S:312 E:315 ||| IN
conducting  ||| S:315 E:326 ||| VBG
multicountry  ||| S:326 E:339 ||| JJ
clinical  ||| S:339 E:348 ||| JJ
trials ||| S:348 E:354 ||| NNS
,  ||| S:354 E:356 ||| ,
sponsors  ||| S:356 E:365 ||| NNS
and  ||| S:365 E:369 ||| CC
investigators  ||| S:369 E:383 ||| NNS
have  ||| S:383 E:388 ||| VBP
to  ||| S:388 E:391 ||| TO
ensure  ||| S:391 E:398 ||| VB
that  ||| S:398 E:403 ||| IN
they  ||| S:403 E:408 ||| PRP
meet  ||| S:408 E:413 ||| VBP
regulatory  ||| S:413 E:424 ||| JJ
requirements  ||| S:424 E:437 ||| NNS
in  ||| S:437 E:440 ||| IN
all  ||| S:440 E:444 ||| DT
countries  ||| S:444 E:454 ||| NNS
in  ||| S:454 E:457 ||| IN
which  ||| S:457 E:463 ||| WDT
the  ||| S:463 E:467 ||| DT
clinical  ||| S:467 E:476 ||| JJ
trials  ||| S:476 E:483 ||| NNS
will  ||| S:483 E:488 ||| MD
be  ||| S:488 E:491 ||| VB
conducted ||| S:491 E:500 ||| VBN
.  ||| S:500 E:502 ||| .
Some  ||| S:502 E:507 ||| DT
of  ||| S:507 E:510 ||| IN
these  ||| S:510 E:516 ||| DT
requirements  ||| S:516 E:529 ||| NNS
include  ||| S:529 E:537 ||| VBP
review  ||| S:537 E:544 ||| NN
and  ||| S:544 E:548 ||| CC
approval  ||| S:548 E:557 ||| NN
by  ||| S:557 E:560 ||| IN
national  ||| S:560 E:569 ||| JJ
drug  ||| S:569 E:574 ||| NN
regulatory  ||| S:574 E:585 ||| JJ
authorities  ||| S:585 E:597 ||| NNS
and  ||| S:597 E:601 ||| CC
recognized  ||| S:601 E:612 ||| VBN
research  ||| S:612 E:621 ||| NN
ethics  ||| S:621 E:628 ||| NNS
committees ||| S:628 E:638 ||| NNS
.  ||| S:638 E:640 ||| .
A  ||| S:640 E:642 ||| DT
limiting  ||| S:642 E:651 ||| JJ
factor  ||| S:651 E:658 ||| NN
to  ||| S:658 E:661 ||| TO
the  ||| S:661 E:665 ||| DT
efficient  ||| S:665 E:675 ||| JJ
conduct  ||| S:675 E:683 ||| NN
of  ||| S:683 E:686 ||| IN
multicountry  ||| S:686 E:699 ||| JJ
clinical  ||| S:699 E:708 ||| JJ
trials  ||| S:708 E:715 ||| NNS
is  ||| S:715 E:718 ||| VBZ
the  ||| S:718 E:722 ||| DT
regulatory  ||| S:722 E:733 ||| JJ
environment  ||| S:733 E:745 ||| NN
in  ||| S:745 E:748 ||| IN
each  ||| S:748 E:753 ||| DT
collaborating  ||| S:753 E:767 ||| JJ
country ||| S:767 E:774 ||| NN
,  ||| S:774 E:776 ||| ,
with  ||| S:776 E:781 ||| IN
significant  ||| S:781 E:793 ||| JJ
differences  ||| S:793 E:805 ||| NNS
determined  ||| S:805 E:816 ||| VBN
by  ||| S:816 E:819 ||| IN
various  ||| S:819 E:827 ||| JJ
factors  ||| S:827 E:835 ||| NNS
including  ||| S:835 E:845 ||| VBG
the  ||| S:845 E:849 ||| DT
laws  ||| S:849 E:854 ||| NNS
and  ||| S:854 E:858 ||| CC
the  ||| S:858 E:862 ||| DT
procedures  ||| S:862 E:873 ||| NNS
used  ||| S:873 E:878 ||| VBN
in  ||| S:878 E:881 ||| IN
each  ||| S:881 E:886 ||| DT
country ||| S:886 E:893 ||| NN
.  ||| S:893 E:895 ||| .
The  ||| S:895 E:899 ||| DT
long  ||| S:899 E:904 ||| JJ
regulatory  ||| S:904 E:915 ||| JJ
processes  ||| S:915 E:925 ||| NNS
in  ||| S:925 E:928 ||| IN
resource-limited  ||| S:928 E:945 ||| JJ
countries  ||| S:945 E:955 ||| NNS
may  ||| S:955 E:959 ||| MD
hinder  ||| S:959 E:966 ||| VB
the  ||| S:966 E:970 ||| DT
efficient  ||| S:970 E:980 ||| JJ
implementation  ||| S:980 E:995 ||| NN
of  ||| S:995 E:998 ||| IN
multisite  ||| S:998 E:1008 ||| JJ
clinical  ||| S:1008 E:1017 ||| JJ
trials ||| S:1017 E:1023 ||| NNS
,  ||| S:1023 E:1025 ||| ,
delaying  ||| S:1025 E:1034 ||| VBG
research  ||| S:1034 E:1043 ||| NN
important  ||| S:1043 E:1053 ||| JJ
to  ||| S:1053 E:1056 ||| TO
the  ||| S:1056 E:1060 ||| DT
health  ||| S:1060 E:1067 ||| NN
of  ||| S:1067 E:1070 ||| IN
populations  ||| S:1070 E:1082 ||| NNS
in  ||| S:1082 E:1085 ||| IN
these  ||| S:1085 E:1091 ||| DT
countries  ||| S:1091 E:1101 ||| NNS
and  ||| S:1101 E:1105 ||| CC
costing  ||| S:1105 E:1113 ||| VBG
millions  ||| S:1113 E:1122 ||| NNS
of  ||| S:1122 E:1125 ||| IN
dollars  ||| S:1125 E:1133 ||| NNS
a  ||| S:1133 E:1135 ||| DT
year ||| S:1135 E:1139 ||| NN
.  ||| S:1139 E:1141 ||| .
